The following list is a summary. Additional criteria apply.

        Inclusion Criteria:

        Patients must meet all of the following criteria to be eligible for study entry.

          -  At least 18 years or older

          -  Histologically or cytologically confirmed, advanced non-squamous or squamous NSCLC

          -  Last line of therapy for advanced non-squamous or squamous NSCLC must be with an
             anti-PD1 or PDL1 antibody with confirmed progression on or after that treatment.
             Patients may have received no more than 3 lines of prior therapy including no more
             than 2 prior lines of therapy containing a PD-(L)-2 antibody. Patients must have
             received prior cisplatin or carboplatin based doublet chemotherapy.

          -  Measurable disease, as defined by RECIST v1.1

          -  Adequate hematologic and end-organ function, defined by the laboratory test results
             within 14 days prior to randomization:

          -  For female patients of childbearing potential and male patients with partners of
             childbearing potential, agreement to use a highly effective form(s) of contraception
             during study treatment that results in a low failure rate of <1% per year when used
             consistently and correctly. Female patients should continue contraception use for 5
             months after the last dose of nivolumab and ipilimumab and for 6 months after the last
             dose of oxaliplatin. Make patients treated with chemotherapy should continue
             contraception use for 7 months after the last dose of chemotherapy. Men should refrain
             from donating sperm during this same period. Such methods include combined (estrogen
             and progestogen containing) hormonal contraception, with another additional barrier
             method always containing a spermicide, intrauterine device (IUD), intrauterine
             hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on
             the understanding that this is the only one partner during the study duration), and
             sexual abstinence.

               -  Oral contraception should always be combined with an additional contraceptive
                  method because of a potential interaction with the study drug. The same rules are
                  valid for male patients involved in this study if they have a partner of
                  childbearing potential. Male patients must always use a condom.

               -  Women who are not postmenopausal (>12 months of non-therapy-induced amenorrhea)
                  or surgically sterile must have a negative serum pregnancy test result within 14
                  days prior to initiation of study drug.

        Exclusion Criteria:

        General Medical Exclusions

          -  Women who are pregnant, lactating, or intending to become pregnant during the study.

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins.

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active
             pneumonitis on screening chest CT scan.

          -  Major surgical procedure other than for diagnosis within 28 days prior to
             randomization or anticipation of need for a major surgical procedure during the course
             of the study.

          -  Prior allogeneic bone marrow transplantation or solid organ transplantation.

        Exclusion Criteria Related to Medications

          -  Treatment with any approved anti-cancer therapy within 2 weeks prior to initiation of
             study treatment.

          -  Treatment with any other investigational agent with therapeutic intent within 21 days
             prior to enrollment.

          -  Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to
             enrollment.